A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Univ of California San Francisco, San Francisco, California, United States
Contact: Principal Investigator (Lawren Vandevrede)CenExcel Rocky Mtn Clin Research, Englewood, Colorado, United States
Contact: Principal Investigator (Meagen Salinas)Mayo Jacksonville, Jacksonville, Florida, United States
Contact: Principal Investigator (Zbigniew K Wszolek)Mayo Clinic, Rochester, Minnesota, United States
Contact: Principal Investigator (James Bower)Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Caen, France
Novartis Investigative Site, Créteil, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Toulouse, France
Novartis Investigative Site, Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site, Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site, Leipzig, Saxony, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Stadtroda, Germany
Klinik für Neurologie (Schwerpunkt Neurodegeneration), Ulm, Germany
Contact: Principal Investigator (Olga aVintonyak)Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Kodaira, Tokyo, Japan
Novartis Investigative Site, Rotterdam, South Holland, Netherlands
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Las Palmas GC, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Seville, Spain